A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.

Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 503.77% and ...

That's the good news. The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine pipelines.

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

These stocks are all trading near their 52-week lows, and could be attractive options to consider. They all possess promising ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Trump would have been convicted Democrats to grill Cabinet picks What Senate races to watch in 2026 U.S. officials hopeful ...